Merck KGaA launches biotech VC fund
This article was originally published in Scrip
Executive Summary
Merck KGaA is launching a venture capital fund to invest in emerging biotechnology companies. Merck Serono Ventures will fund biotech start-ups for neurodegenerative diseases, oncology and autoimmune and inflammatory diseases to complement its core therapeutic areas.